Log in

NASDAQ:CRBPCorbus Pharmaceuticals Stock Price, Forecast & News

$7.95
-0.44 (-5.24 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.95
Now: $7.95
$8.50
50-Day Range
$6.50
MA: $7.44
$8.39
52-Week Range
$3.29
Now: $7.95
$8.78
Volume1.10 million shs
Average Volume1.16 million shs
Market Capitalization$576.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Read More
Corbus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.14 million
Book Value$0.10 per share

Profitability

Net Income$-71,450,000.00
Net Margins-207.87%

Miscellaneous

Employees141
Market Cap$576.30 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRBP shares have increased by 93.0% and is now trading at $7.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Corbus Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Corbus Pharmaceuticals.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) posted its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.03. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $1.64 million. Corbus Pharmaceuticals had a negative return on equity of 282.91% and a negative net margin of 207.87%. View Corbus Pharmaceuticals' earnings history.

What price target have analysts set for CRBP?

7 brokerages have issued 1-year price objectives for Corbus Pharmaceuticals' shares. Their forecasts range from $22.00 to $112.00. On average, they expect Corbus Pharmaceuticals' share price to reach $39.00 in the next year. This suggests a possible upside of 390.6% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

Has Corbus Pharmaceuticals been receiving favorable news coverage?

News coverage about CRBP stock has been trending somewhat negative on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Corbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 45, Pay $810.55k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 62, Pay $520k)
  • Dr. Barbara White, Head of Research & Chief Medical Officer (Age 70, Pay $570.7k)
  • Dr. Robert Paul Discordia Ph.D., Chief Operating Officer (Age 56)
  • Ted Jenkins, Sr. Director of Investor Relations & Communications

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $7.95.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $576.30 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.